Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"Donepezil"”.
-
Changes in Brain Functional Connectivity Following Donepezil Treatment in Alzheimer's Disease
… treatment with the cholinesterase inhibitor, donepezil. The ROIs were selected on the basis of their association with cholinergic neurotransmission, AD neuropathology, and neurocognitive deficits in AD. These ROIs included the medial septal nuclei, left and right hippocampi, left Broca's area …
-
Causal Inference Methods for Estimation of Survival and General Health Status Measures of Alzheimer’s Disease Patients
… prevalent classes of Alzheimer’s disease drugs, Donepezil and Memantine, and their combined use on Survival and General Health Status Measures of Alzheimer's disease patients for the first five years after initial diagnosis. We carried out a thorough causal inference study using doubly robust …
-
Assessing the acetylcholinesterase inhibitory potential of novel pharmacophores for potential treatment of Alzheimer’s disease
… AChEI effects of active pharmacophores and donepezil were assessed using a checkerboard assay. The sulforhodamine B assay was employed to determine the active compounds and synergistic combinations cytotoxic potential after 72 h in SH-SY5Y neuroblastoma and brain endothelial (bEnd.5) cells. …
-
Cholinergic enhancing strategies and brain neuroplasticity. From preclinical evidence to clinical applications.
… a double-blind trial investigating if the ChE-I donepezil and choline alphoscerate in combination are more effective that donepezil alone. Over the 24-month observation period, patients of the reference group showed a moderate time-dependent worsening in all the parameters investigated. Treatment …
-
Donepezil’s Effect on Cardiac Function in Patients with Alzheimer’s Disease through an In Vivo, Non Invasive Measure of Cardiac Autonomic Function
… was to explore the effects of the medication Donepezil (Aricept®) on cardiac autonomic function for individuals diagnosed with mild to moderate (probable) Alzheimer’s disease (AD). Using age (± 3 years) and gender matched controls, differences in heart rate variability (HRV) among individuals …
-
Long Term Outcome and Prediction Models of Cognition, Activities of Daily Living and Nursing Home Placement in Alzheimer’s Disease with Cholinesterase Inhibitor Treatment
… 6 months during the following 3 years. I. 435 donepezil-treated patients II. 843 patients treated with donepezil, rivastigmine or galantamine III. 790 patients treated with donepezil, rivastigmine or galantamine IV. 880 patients treated with donepezil, rivastigmine or galantamine Results I. …
-
Acetylcholine and posttraumatic stress disorder.
… suffering these symptoms have been demonstrated. Donepezil hydrochloride, a reversible inhibitor of the enzyme acetylcholinesterase, is used in the treatment of conditions with difficulties in cognitive function, but has not been used in PTSD. The aim of this thesis was to determine (1) whether …
-
Präsynaptische Wirkungen von Cholinesterase-Hemmstoffen im Neocortex des Menschen und der Ratte
… etwa folgende Reihenfolge der Wirksamkeit ergab: Donepezil = <br>Physostigmin > Tacrin > Galanthamin; Rivastigmin war unwirksam. Im Neocortex des <br>Menschen ergab sich bezogen auf die inhibitorischen Potenzen zwar die gleiche <br>Reihenfolge, jedoch waren die maximalen Hemmeffekte deutlich …
-
Neuromuscular Dysfunction as a Novel Indicator for Alzheimer's Disease and Response to Intervention in the 5xFAD Model
… running or an acetylcholinesterase inhibitor donepezil treatment, started before neuromuscular decline, would delay neuromuscular impairment in 5xFAD mice. Using 3-month-old 5xFAD and wild type (WT) littermates, we provided voluntary wheel access for 4 weeks and assessed exercise capacity, …
-
Cognitive and Non-Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease
… translation across species. In our study, donepezil had minor effects on the performance of 5xFAD mice in the 5-CSRTT, a touchscreen task evaluating attention. Additionally, 5xFAD mice do not demonstrate impairments in the PVD task, which assesses visual discrimination/ cognitive …
-
Cholinesterase Inhibitors and Neuropathology of Cerebrovascular Disease and Other Dementias in Patients with Alzheimer’s Disease: A Study of NACC Autopsy and Medical History Data, 2005 – 2017
… pathology was positively associated with use of donepezil (OR: 1.43; 95% CI: 1.04 – 1.96). Our findings suggest some value in further exploring the pathological impacts of ChEI.
-
Model-Based Measures Of Interrater Agreement
… being similar to the binding mode of donepezil. The hydrophobic and &pi-&pi interactions play an important role in the potent inhibitory activities. Based on these results, a series of JWS derivatives and 1,8-naphthalimide analogs were synthesized as potential MTDLs and tested for …
-
A Neuroprotective Role for Mir-1017, a Non-Canonical Mirna
… receptor (AchR) activity antagonist, Donepezil, which likewise resulted in higher GFP expression. Together this suggests that Da2 transcription is modulated by acetylcholine neurotransmission. Consistent with a role in dampening AchR activity miR-1017 mutant flies exhibit a …
-
Long-term treatment response, predictors and biochemical markers in Alzheimer’s disease.
… the cholinesterase inhibitors (ChEIs) (tacrine, donepezil, rivastigmine, galantamine) were introduced as treatments for AD. Multiple short-term randomised clinical trials of ChEI treatment show beneficial effects on cognition, global functioning and activities of daily living in AD. Whether the …
-
Development and Characterization of Sustained-Release Formulations via Novel Hot Melt Extrusion Techniques
… the matrix; (3) to develop of sustained-released donepezil hydrochloride (DH) formulations with various hydrophobic carriers utilizing HME technique alone to optimize hot melt process parameters for obtaining the desirable sustained release profile ; (4) to develop and evaluate a sustained-release …
-
Changes in cerebral glucose metabolism in patients with Parkinson’s disease with dementia after cholinesterase inhibitor therapy
… of PDD. Patients were treated with either donepezil or galantamine. End point was when patients were treated for at least 3 months and when the patient or family members reported improved cognition. 18F-FDG PET scan was done before initiation of treatment and after completion drug trial. …
-
Pharmacological modulation of learning and memory in mice and zebrafish: Implications for Alzheimer’s disease animal models
… and memory in rodents and in humans such as donepezil and scopolamine. Donepezil was found to reduce the ASR and habituation of ASR in zebrafish larvae, consistent with some reports in rodents. Scopolamine treatment of zebrafish larvae produced a biphasic effect on non-cognitive measures such …
-
Repurposing Alzheimer’s disease medications in a drug combination for the study of the crosstalk between cell apoptosis and autophagy in the modulation of cell death in chronic myeloid leukaemia
… concentrations (1, 5 and 10 μM) of Memantine and Donepezil (AD drugs) were shown to be non-toxic in this study, as they induced no measurable cell death in both cell lines tested, with Memantine (1 μM) increasing the viability of HEK293T (the AD cell model) by 41% (p < 0.05). Following the results …
-
CUMULATIVE ANTICHOLINERGIC BURDEN AND ASSOCIATED OUTCOMES AMONG OLDER ADULTS WITH ALZHEIMER’S DISEASE
… a diagnosis of AD initiating any of the ChEIs (donepezil, rivastigmine, or galantamine). The cumulative anticholinergic burden was calculated based on the Anticholinergic Cognitive Burden scale and patient-specific dosing using the defined daily dose over the defined period after ChEIs …